Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Crinetics Pharmaceuticals Inc Stock Research

CRNX

29.17USD+0.55(+1.92%)Market Closed
Watchlist

Market Summary

USD29.17+0.55
Market Closed
1.92%

CRNX Alerts

CRNX Stock Price

CRNX RSI Chart

CRNX Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-8.51

Price/Sales (Trailing)

323.75

Price/Free Cashflow

-9.7

CRNX Price/Sales (Trailing)

CRNX Profitability

Return on Equity

-62.53%

Return on Assets

-55.82%

Free Cashflow Yield

-10.31%

CRNX Fundamentals

CRNX Revenue

Revenue (TTM)

4.8M

Revenue Y/Y

125.06%

Revenue Q/Q

-63.12%

CRNX Earnings

Earnings (TTM)

-183.9M

Earnings Y/Y

-20.3%

Earnings Q/Q

-10.84%

Price Action

52 Week Range

31.00
(Low)(High)

Last 7 days

0.3%

Last 30 days

78.3%

Last 90 days

54.0%

Trailing 12 Months

43.7%

CRNX Financial Health

Current Ratio

11.6

CRNX Investor Care

Shares Dilution (1Y)

4.11%

Diluted EPS (TTM)

-3.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for CRNX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-14
Struthers Richard Scott
acquired
19,100
1.91
10,000
president & ceo
2023-07-13
Struthers Richard Scott
sold
-288,095
20.35
-14,157
president & ceo
2023-07-12
Struthers Richard Scott
sold
-231,128
20.17
-11,459
president & ceo
2023-07-11
Struthers Richard Scott
sold
-491,094
20.14
-24,384
president & ceo
2023-06-20
Wilson Marc
acquired
185,600
9.28
20,000
cfo
2023-06-20
Wilson Marc
sold
-617,403
19.9665
-30,922
cfo
2023-06-16
Vivaldi Coelho Rogerio
acquired
-
-
6,000
-
2023-06-16
Struthers Richard Scott
sold
-1,040,500
20.81
-50,000
president & ceo
2023-06-16
Okey Stephanie
acquired
-
-
6,000
-
2023-06-16
Nichols Weston
acquired
-
-
6,000
-

1–10 of 50

Which funds bought or sold CRNX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-08-24
PERCEPTIVE ADVISORS LLC
reduced
-45.23
-22,007,700
35,083,800
1.01%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-3.27
72,212
917,867
-%
2023-08-21
OSAIC HOLDINGS, INC.
added
382
35,432
43,461
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
reduced
-27.17
-142,000
635,000
0.01%
2023-08-16
Nuveen Asset Management, LLC
added
176
4,187,090
6,184,090
-%
2023-08-15
GOLDMAN SACHS GROUP INC
added
18.19
2,725,150
11,079,500
-%
2023-08-15
WELLS FARGO & COMPANY/MN
added
42.44
297,710
795,313
-%
2023-08-15
ALLIANCEBERNSTEIN L.P.
unchanged
-
100,352
922,624
-%
2023-08-15
NATIXIS ADVISORS, L.P.
added
0.82
42,000
367,000
-%
2023-08-15
EVENTIDE ASSET MANAGEMENT, LLC
unchanged
-
852,145
7,834,520
0.13%

1–10 of 48

Latest Funds Activity

Are funds buying CRNX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CRNX
No. of Funds

Schedule 13G FIlings of Crinetics Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Sep 18, 2023
point72 asset management, l.p.
5.6%
3,719,200
SC 13G
Feb 14, 2023
braidwell lp
6.45%
3,469,674
SC 13G
Feb 14, 2023
biotechnology value fund l p
2.7%
1,447,317
SC 13G/A
Feb 14, 2023
orbimed advisors llc
5.0%
2,710,710
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 08, 2023
driehaus capital management llc
10.45%
5,624,744
SC 13G/A
Feb 06, 2023
wellington management group llp
5.21%
2,804,485
SC 13G
Jan 31, 2023
blackrock inc.
7.3%
3,917,489
SC 13G/A
Apr 26, 2022
perceptive advisors llc
10.0%
5,333,532
SC 13D/A
Apr 21, 2022
perceptive advisors llc
10.0%
5,333,532
SC 13D/A

Recent SEC filings of Crinetics Pharmaceuticals

View All Filings
Date Filed Form Type Document
Sep 18, 2023
SC 13G
Major Ownership Report
Sep 13, 2023
424B5
Prospectus Filed
Sep 13, 2023
8-K
Current Report
Sep 11, 2023
424B5
Prospectus Filed
Sep 11, 2023
8-K
Current Report
Aug 16, 2023
4
Insider Trading
Aug 08, 2023
10-Q
Quarterly Report
Aug 08, 2023
8-K
Current Report
Jul 13, 2023
144
Notice of Insider Sale Intent
Jul 13, 2023
4
Insider Trading

Peers (Alternatives to Crinetics Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
271.4B
56.0B
2.30% 9.45%
31.25
4.84
-2.31% -31.27%
265.4B
1.8B
-1.67% 25.43%
-153.19
146.56
69.45% 14.65%
90.8B
9.5B
0.45% 22.78%
26.99
9.56
13.83% 5.33%
89.0B
12.7B
-1.51% 18.09%
20.7
7.02
-10.94% -24.40%
21.9B
1.2B
-7.00% -17.21%
-20.61
17.72
39.94% -8.44%
11.0B
1.0B
3.70% 3.57%
-12.12
10.97
20.15% -79.16%
10.5B
2.1B
-3.12% 8.08%
12.05
4.98
18.01% 38.16%
MID-CAP
3.1B
225.6M
0.04% -28.00%
-5.53
13.59
-2.11% 21.02%
3.0B
-
-10.01% 147.80%
-9.03
-
- -28.88%
2.6B
402.9M
-2.14% -20.15%
-3.59
6.42
20.50% -42.46%
1.9B
27.2M
-14.18% -57.07%
-2.57
69.63
- -14.43%
SMALL-CAP
3.1B
-
-2.94% -39.70%
-7.31
33.28
34.30% -149.91%
1.3B
302.9M
-16.58% -4.84%
11.23
4.28
77.72% 112.02%
281.2M
152.5M
-11.67% 38.41%
37.75
1.84
127.84% 103.41%
29.9M
-
1.35% 3552.08%
-0.65
-
- -31.51%

Crinetics Pharmaceuticals News

GuruFocus.com
Opaleye Management Inc. Reduces Stake in Harrow Health Inc..
GuruFocus.com,
6 hours ago
Marketscreener.com
BioWorld Online
Financings for Sept. 13, 2023.
BioWorld Online,
8 days ago
Investing.com UK
The Motley Fool
Investor's Business Daily

Returns for CRNX

Cumulative Returns on CRNX

-1.7%


5-Year Cumulative Returns

22.0%


3-Year Cumulative Returns

Risks for CRNX

What is the probability of a big loss on CRNX?

100%


Probability that Crinetics Pharmaceuticals stock will be more than 20% underwater in next one year

85.4%


Probability that Crinetics Pharmaceuticals stock will be more than 30% underwater in next one year.

53.9%


Probability that Crinetics Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CRNX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Crinetics Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Financials for Crinetics Pharmaceuticals

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q3
Revenue12.8%4,834,0004,285,0004,737,0005,370,6677,140,00012,524,0001,078,000735,000392,000897,000897,0001,193,0001,653,0001,696,0002,353,0002,428,0002,175,0002,267,0002,442,0002,071,4001,700,800
Operating Expenses5.6%196,817,000186,318,000172,619,000156,320,000140,215,000122,820,000108,780,00075,024,00068,768,00066,051,00062,467,00055,025,00049,702,00042,586,00035,581,00031,138,00023,955,00018,351,00014,486,00011,172,00010,857,333
  S&GA Expenses6.2%48,731,00045,877,00042,394,00038,482,00032,784,00027,897,00024,525,00018,026,00016,457,00015,616,00014,354,00013,519,00012,688,00010,509,0008,567,0006,659,0004,565,0003,324,0002,598,0001,939,0001,962,667
  R&D Expenses5.4%148,086,000140,441,000130,225,000117,838,000107,431,00094,923,00084,255,00056,998,00052,311,00050,435,00048,113,00041,506,00037,014,00032,077,00027,014,00024,479,00019,390,00015,027,00011,888,0009,233,0008,894,667
EBITDA------106,718,000-106,703,000-106,719,000-72,856,000-49,462,000-49,478,000-49,492,000-49,527,000-26,241,000-26,330,000-26,484,000------
EBITDA Margin------14.95-8.52-99.00-1,026-126-55.16-55.18-41.51-15.87-15.52-11.26------
Interest Expenses--------------------8,00010,000
EBT Margin------15.08-8.59-99.85-1,039-128-56.21-56.21-42.26-16.40-15.99-11.52------
Net Income-4.9%-183,890,000-175,286,000-163,918,000-149,721,000-135,647,000-119,367,000-107,641,000-73,812,000-66,720,000-62,830,000-58,766,000-50,422,000-44,368,000-37,526,000-30,667,000-27,115,000-21,141,000-15,935,000-12,015,000-9,157,000-8,848,000
Net Income Margin100.0%--40.91-34.60-27.88-19.00-9.53-99.85-1,039-170-70.04-65.51-42.26-26.84-22.13-------
Free Cashflow100.0%--143,965,000-116,861,000-104,297,000-90,949,000-82,471,000-89,024,000-62,213,000-59,733,000-55,239,000-51,996,000-46,873,000-39,689,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-6.6%29331435238542233335120921716418320021712413014315516717117775.00
  Current Assets-6.7%28530534537841632834520421115817719421111712313514815916717170.00
    Cash Equivalents-4.0%40.0041.0033.0031.0062.0014620116217910693.0011816151.0041.0067.0060.0063.0045.0017069.00
  Net PPE-1.3%3.003.004.004.003.003.003.003.003.003.003.003.004.004.004.004.004.004.004.004.002.00
Liabilities16.2%39.0034.0036.0034.0036.0030.0019.0016.0015.0014.0015.0013.0014.0015.0013.0013.0013.0014.0011.009.007.00
  Current Liabilities23.9%33.0026.0028.0025.0026.0020.0016.0012.0012.0010.0010.009.0010.0011.008.008.008.009.008.006.006.00
Shareholder's Equity-9.4%254280316351386303332194201149169187203108117130142152160168-
  Retained Earnings-10.5%-536-485-439-394-352-309-275-244-216-190-167-146-127-111-93.80-79.25-64.82-52.40-43.38-34.88-27.30
  Additional Paid-In Capital-------------------2042022.00
Shares Outstanding1.3%55.0054.0054.0054.0053.0048.0048.0038.0037.0033.0033.0030.0031.0024.0024.0024.0024.0024.0012.0020.002.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-12.5%-160,139-142,380-115,205-102,897-90,091-82,064-88,588-81,627-73,958-69,864-62,027-59,536-55,139-51,852-46,381-38,943-31,029-22,811-19,459-15,961-12,711
  Share Based Compensation9.9%33,65330,60928,26825,47822,59919,70117,35215,16513,39111,68610,4279,2878,3607,4136,2945,3104,2312,9212,3201,544840
Cashflow From Investing251.3%123,866-81,841-173,980-312,631-326,478-132,369-56,48336,42318,61616,380217-3,71441,56633,40741,667-64,191-84,890-94,802-119,458-1,008-775
Cashflow From Financing-88.1%14,333120,667121,963285,704300,091254,402252,67988,92073,299108,146114,571114,491114,6716,52967.0059.00107,227106,706170,198177,26070,060

CRNX Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenues$ 988$ 439$ 3,667$ 3,570
Operating expenses:    
Research and development40,64032,99579,10861,247
General and administrative13,34310,48925,53219,195
Total operating expenses53,98343,484104,64080,442
Loss from operations(52,995)(43,045)(100,973)(76,872)
Other income (expense):    
Interest income2,1077204,145913
Other income (expense), net(91)(81)(146)(64)
Change in valuation of derivative asset031031
Total other income, net2,0166703,999880
Loss before equity method investment(50,979)(42,375)(96,974)(75,992)
Loss on equity method investment000(1,010)
Net loss$ (50,979)$ (42,375)$ (96,974)$ (77,002)
Net loss per share:    
Net loss per share - basic$ (0.94)$ (0.81)$ (1.79)$ (1.54)
Net loss per share - diluted$ (0.94)$ (0.81)$ (1.79)$ (1.54)
Weighted average shares - basic54,27552,52254,09250,130
Weighted average shares - diluted54,27552,52254,09250,130
Other comprehensive income (loss):    
Unrealized gain (loss) on investment securities$ 809$ (1,427)$ 2,226$ (3,237)
Comprehensive loss$ (50,170)$ (43,802)$ (94,748)$ (80,239)

CRNX Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 39,553$ 32,672
Investment securities224,976301,753
Prepaid expenses and other current assets20,28110,759
Total current assets284,810345,184
Property and equipment, net3,2233,500
Operating lease right-of-use asset1,2531,486
Derivative asset668668
Restricted cash1,3001,301
Other assets2,00037
Total assets293,254352,176
Current liabilities:  
Accounts payable and accrued expenses20,82515,351
Accrued compensation and related expenses8,5969,081
Deferred revenue2,0802,240
Operating lease liability1,1091,051
Total current liabilities32,61027,723
Operating lease liability, non-current1,4562,024
Deferred revenue, non-current5,0726,101
Total liabilities39,13835,848
Commitments and contingencies (Note 7)
Stockholders’ equity:  
Preferred stock, $0.001 par; 10,000 shares authorized; no shares issued or outstanding on June 30, 2023 or December 31, 202200
Common stock and paid-in capital, $0.001 par; 200,000 shares authorized; 54,682 shares issued and outstanding on June 30, 2023; 53,877 shares issued and outstanding on December 31, 2022791,968759,432
Accumulated other comprehensive loss(1,705)(3,931)
Accumulated deficit(536,147)(439,173)
Total stockholders’ equity254,116316,328
Total liabilities and stockholders’ equity$ 293,254$ 352,176
Scott R. Struthers
140
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.